Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia.
OBJECTIVE
Tetrahydrobiopterin (BH4) is an essential co-factor for the synthesis of nitric oxide (NO), and BH4 deficiency may cause impaired NO synthase (NOS) activity. We studied whether BH4 deficiency contributes to the coronary microcirculatory dysfunction observed in patients with hypercholesterolaemia.


METHODS
Myocardial blood flow (MBF; ml min(-1) g(-1)) was measured at rest, during adenosine-induced (140 microg kg(-1) min(-1) over 7 min) hyperaemia (mainly non-endothelium dependent) and immediately after supine bicycle exercise (endothelium-dependent) stress in ten healthy volunteers and in nine hypercholesterolaemic subjects using 15O-labelled water and positron emission tomography. Measurements were repeated 60 min later, after intravenous infusion of BH4 (10 mg kg(-1) body weight over 30 min). Adenosine-induced hyperaemic MBF is considered to represent (near) maximal flow. Flow reserve utilisation was calculated as the ratio of exercise-induced to adenosine-induced hyperaemic MBF and expressed as percent to indicate how much of the maximal (adenosine-induced) hyperaemia can be achieved by bicycle stress.


RESULTS
BH4 increased exercise-induced hyperaemia in controls (2.96+/-0.58 vs 3.41+/-0.73 ml min(-1) g(-1), p<0.05) and hypercholesterolaemic subjects (2.47+/-0.78 vs 2.70+/-0.72 ml min(-1) g(-1), p<0.01) but had no influence on MBF at rest or during adenosine-induced hyperaemia in controls (4.52+/-1.10 vs 4.85+/-0.45 ml min(-1) g(-1), p=NS) or hypercholesterolaemic subjects (4.86+/-1.18 vs 4.53+/-0.93 ml min(-1) g(-1), p=NS). Flow reserve utilisation remained unchanged in controls (70+/-17% vs 71+/-19%, p=NS) but increased significantly in hypercholesterolaemic subjects (53+/-15% vs 66+/-14%, p<0.05).


CONCLUSIONS
BH4 restores flow reserve utilisation of the coronary microcirculation in hypercholesterolaemic subjects, suggesting that BH4 deficiency may contribute to coronary microcirculatory dysfunction in hypercholesterolaemia.
Wyss
Christophe A
CA
Nuclear Cardiology, Cardiovascular Center, University Hospital, C NUK 32, Ramistrasse 100, CH 8091, Zurich, Switzerland.
Koepfli
Pascal
P
Namdar
Mehdi
M
Siegrist
Patrick T
PT
Luscher
Thomas F
TF
Camici
Paolo G
PG
Kaufmann
Philipp A
PA
D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage; D001708:Biopterins / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001783:Blood Flow Velocity; D005080:Exercise Test; D006801:Humans; D006937:Hypercholesterolemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D007262:Infusions, Intravenous; D008297:Male; D008833:Microcirculation / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D008875:Middle Aged; D011877:Radionuclide Imaging; D020127:Recovery of Function / Q000187:drug effects*; D016896:Treatment Outcome
D000975:Antioxidants; D001708:Biopterins; C003402:sapropterin